ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study…
MUNICH, April 18, 2026 /PRNewswire/ -- The largest real-world study of its kind, presented today at ESCMID Global 2026, shows that…
April 15, 2026 01:00 ET | Source: BioVersys BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) -- Poster presentations to feature…